Market Overview:
The global anti-migraine drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of migraine, rising awareness about available treatment options, and growing demand for effective and safe drugs. The triptans segment is expected to account for the largest share of the global anti-migraine drugs market in 2018. This segment is projected to grow at a CAGR of 5.9% during the forecast period from 2018 to 2030 due to their high efficacy and safety profile. The ergots segment is projected to grow at a CAGR of 6% during the forecast period from 2018to 2030 due its long history of use in migraine prophylaxis and its relatively low incidenceof adverse effects compared with other drug classes used for migraineprophylaxis such as beta blockersand anticonvulsants . However, owingto their potentialfor causing serious adverse effects such as ergotism, this classof drugsis used less frequently than triptans or other newer agents .
Product Definition:
Anti-migraine drugs are medications used to prevent or treat migraine headaches. They include over-the-counter (OTC) medications such as ibuprofen and aspirin, as well as prescription medications. Anti-migraine drugs work by blocking the action of certain chemicals in the brain that are involved in causing migraines.
Triptans:
Triptans are drugs that are used for the treatment of migraine. They act by reducing pain and inflammation in the brain. Triptans work by binding to serotonin (5-HT1B/1D) receptors, which is why they can help relieve both chronic and acute pain.
Ergots:
The main active ingredients in ergot alkaloids are ergoline and lysine. The drug is used to treat patients suffering from chronic migraine, which affects one out of every four people at some point in their lives. Ergots are also used to prevent migraines as they have been found effective in trials when added to food products such as bread and beer, however the Food and Drug Administration (FDA) has not approved this use yet.
Application Insights:
The women¢â‚¬â„¢s application segment held the largest share of over 70.0% in 2017. Migraine is more prevalent in women as compared to men due to biological factors such as higher prevalence of migraine among females than males. According to a study published by NCBI, it was found that out of total migraine cases, nearly 50% were observed in females while 30% were observed in males.
Men are also increasingly suffering from migraines but the incidence rate is less compared to that seen in female patients. The male population above 40 years old has started registering an increasing number of migraines due to rising awareness about headaches and their treatment options through anti-migraine drugs which are available for men as well as female patients only.
Regional Analysis:
North America accounted for the largest share of over 40.0% in 2017. This is due to the higher prevalence of migraine and other associated disorders, such as cluster headaches, epilepsy, and motion sickness among others in this region as compared to other regions. For instance, around 15 million people suffer from chronic migraines in U.S., which is nearly four times more than India (6 million).
Asia Pacific anti-migraine drugs market by country; China (Shanghai), India (Bangalore), Australia (Melbourne), Japan (Tokyo) & South Korea & Hong Kong SAR & Taiwan Province Taiwan Source: IMS Health Pvt Ltd.
Growth Factors:
- Increasing prevalence of migraine
- Growing awareness about the available treatment options for migraine
- Rising demand for effective and safe anti-migraine drugs
- Technological advancements in the field of anti-migraine drugs development
- Availability of generic versions of branded anti-migraine drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-Migraine Drugs Market Research Report
By Type
Triptans, Ergots, Others
By Application
Women, Men
By Companies
Eli Lilly, Abbott, Eisai, Allergan, Endo, GlaxoSmithKline, Impax Laboratories, Pfizer, AstraZeneca, Bayer, Eli Lilly, Merck, Teva, Amgen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Anti-Migraine Drugs Market Report Segments:
The global Anti-Migraine Drugs market is segmented on the basis of:
Types
Triptans, Ergots, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Women, Men
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- Abbott
- Eisai
- Allergan
- Endo
- GlaxoSmithKline
- Impax Laboratories
- Pfizer
- AstraZeneca
- Bayer
- Eli Lilly
- Merck
- Teva
- Amgen
Highlights of The Anti-Migraine Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Triptans
- Ergots
- Others
- By Application:
- Women
- Men
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-Migraine Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anti-migraine drugs are medications that are used to relieve the symptoms of migraine, including pain, pressure, and redness in the eyes. These drugs can be taken as pills or injections.
Some of the major companies in the anti-migraine drugs market are Eli Lilly, Abbott, Eisai, Allergan, Endo, GlaxoSmithKline, Impax Laboratories, Pfizer, AstraZeneca, Bayer, Eli Lilly, Merck, Teva, Amgen.
The anti-migraine drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anti-Migraine Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anti-Migraine Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anti-Migraine Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anti-Migraine Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anti-Migraine Drugs Market Size & Forecast, 2020-2028
4.5.1 Anti-Migraine Drugs Market Size and Y-o-Y Growth
4.5.2 Anti-Migraine Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Triptans
5.2.2 Ergots
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Women
6.2.2 Men
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anti-Migraine Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anti-Migraine Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Triptans
9.6.2 Ergots
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Women
9.10.2 Men
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Triptans
10.6.2 Ergots
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Women
10.10.2 Men
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Triptans
11.6.2 Ergots
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Women
11.10.2 Men
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Triptans
12.6.2 Ergots
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Women
12.10.2 Men
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Triptans
13.6.2 Ergots
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Women
13.10.2 Men
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anti-Migraine Drugs Market: Competitive Dashboard
14.2 Global Anti-Migraine Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly
14.3.2 Abbott
14.3.3 Eisai
14.3.4 Allergan
14.3.5 Endo
14.3.6 GlaxoSmithKline
14.3.7 Impax Laboratories
14.3.8 Pfizer
14.3.9 AstraZeneca
14.3.10 Bayer
14.3.11 Eli Lilly
14.3.12 Merck
14.3.13 Teva
14.3.14 Amgen
